Top Japan drugmakers in biomarker development pact

DNA computer
Biomarker pact

Top Japanese drugmakers Astellas Pharma, Daiichi Sankyo and Takeda Pharmaceutical announced a pact to develop a biomarker database of healthy patients that will be managed by a Netherlands-based CRO and could be used in clinical studies and shared with in-house and outside researchers.

Under the terms, each company will use their own facilities to collect and analyze biomarker data and meld the data into a wider pool--with the findings to be released publicly.

"Samples will be acquired at a clinical research organization associated with Leiden University in the Netherlands and be under the supervision of Dr. Thomas Hankemeier, professor at Leiden University," according to a joint statement.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

"The analysis results will be mainly utilized in the companies’ therapeutic areas of focus. Data gained from this analysis will be publicized so that it may be widely utilized in various types of drug discovery research to meet patients’ unmet needs."

The effort by the companies, according to the statement, will feed into therapeutic focus areas. In the case of Astellas, these will be urology, oncology, immunology, nephrology, neuroscience, muscle diseases and ophthalmology.

For Daiichi Sankyo, the areas listed covered oncology and newer targets in pain, CNS (central nervous system) diseases, heart and kidney disease and rare diseases; for Takeda, gastroenterology, oncology, CNS and vaccines.

- here's the story from PMLiVE
- and the release


Suggested Articles

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

Hoping to expand its hospital portfolio in Japan, the Novartis generics unit is buying Aspen Pharmacare's operations there for up to €400 million.

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.